证券日报网讯海特生物（300683）11月14日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司股东人数为19，861户。 ...

格隆汇11月11日丨海特生物(300683.SZ)公布，近日取得湖北省药品监督管理局换发的《药品生产许可 证》，同意《药品生产许可证》药品委托或受托情况的变更申请。新增受托生产品种：注射用甲磺酸萘 莫司他（仅限注册申报使用），委托方：福建大谱生物医药有限公司。 ...

格隆汇11月11日丨海特生物(300683.SZ)公布，近日取得湖北省药品监督管理局换发的《药品生产许可 证》，同意《药品生产许可证》药品委托或受托情况的变更申请。新增受托生产品种：注射用甲磺酸萘 莫司他（仅限注册申报使用），委托方：福建大谱生物医药有限公司。 ...

企业名称：武汉海特生物制药股份有限公司 注册地址：武汉经济技术开发区海特科技园 证券代码：300683 证券简称：海特生物 公告编号：2025-049 武汉海特生物制药股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 武汉海特生物制药股份有限公司（以下简称"公司"）于近日取得湖北省药 品监督管理局换发的《药品生产许可证》，同意《药品生产许可证》药品委托或 受托情况的变更申请。新增受托生产品种：注射用甲磺酸萘莫司他（仅限注册申 报使用），委托方：福建大谱生物医药有限公司。变更后的《药品生产许可证》 具体内容如下： 一、《药品生产许可证》基本情况 社会信用代码：91420100724667038L 法定代表人：陈亚 企业负责人：陈亚 质量负责人：赵满岐 有效期至：2030 年 8 月 17 日 许可证编号：鄂 20200224 分类码：AshCh 生产地址和生产范围：1.湖北省武汉经济技术开发区海特科技园 治疗用生 物制品（注射用抗乙型肝炎转移因子、注射用鼠神经生长因子、注射用埃普奈明）、 冻干粉针剂、散剂、小容量注射 ...

Core Insights - The medical services sector experienced a rise of 0.89% on November 10, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4018.6, up 0.53%, while the Shenzhen Component Index closed at 13427.61, up 0.18% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.87, with an increase of 8.94% and a trading volume of 99,000 shares, amounting to a transaction value of 330 million [1] - Tongce Medical (600763) saw a closing price of 44.51, up 5.00%, with a trading volume of 174,500 shares and a transaction value of 769 million [1] - Puri Eye Hospital (301239) closed at 38.73, up 4.96%, with a trading volume of 38,500 shares and a transaction value of 148 million [1] - Other notable performers include Hite Bio (300683) with a 4.85% increase, and Aier Eye Hospital (300015) with a 3.40% increase [1] Capital Flow Analysis - The medical services sector saw a net outflow of 185 million from institutional investors, while retail investors contributed a net inflow of 84.71 million [2] - Major stocks like Aier Eye Hospital (300015) experienced a net inflow of 300 million from institutional investors, despite a significant outflow from retail investors [3] - Tongce Medical (600763) had a net inflow of 115 million from institutional investors, but also faced outflows from retail investors [3]

Core Viewpoint - Recent data indicates a significant rise in influenza activity in China, with a notable increase in patients visiting hospitals for treatment, prompting the need for early antiviral therapy and consideration of various factors in drug selection [1][2][3] Group 1: Influenza Activity - The latest report from the Chinese Center for Disease Control and Prevention shows a marked increase in influenza activity, particularly in southern provinces, with the percentage of influenza-like illness (ILI) cases reported at 4.6%, up from 4.1% the previous week [2] - Northern provinces reported an ILI percentage of 5.1%, significantly higher than the previous week's 3.7% and above levels from 2022, 2023, and 2024 [2] - A total of 347 influenza-like illness outbreaks were reported nationwide, with 245 cases identified as A(H3N2) [2] Group 2: Treatment and Drug Approval - The increase in influenza cases has led to a rise in hospital visits, particularly in pediatric departments, with doctors recommending early antiviral treatment within 48 hours of symptom onset [4] - Oseltamivir remains the preferred antiviral treatment, especially for children and immunocompromised patients, with over 120 approvals for related products from various companies [4][5] - The market for oseltamivir is dominated by Dongyangguang Pharmaceutical, holding over 70% market share in the past three years [4] Group 3: New Drug Developments - Several new RNA polymerase inhibitors have been approved in China, with the year 2025 being referred to as the "Year of Domestic Influenza New Drugs" [1][6] - Roche's Marbofloxacin has seen a significant increase in demand, with supply pressures leading to local production initiatives [6][7] - Other domestic companies, such as Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, have also launched new antiviral drugs, contributing to a broader range of treatment options for influenza [7][8] Group 4: Market Dynamics - The price of Marbofloxacin ranges from 195 to 234 yuan per pack, with no adjustments made by Roche despite increased demand [7] - Companies like Haizheng Pharmaceutical have reported a significant rise in demand for their antiviral products, with ongoing supply guarantees in place [8][9] - The market is seeing increased competition as more domestic firms enter the RNA polymerase inhibitor space, with several products currently in clinical trials or awaiting approval [9]

北京中伦（武汉）律师事务所 关于武汉海特生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年十一月 湖北省武汉市江汉区建设大道 568 号新世界国贸大厦 I 座 50 层 邮编：430022 50/F, Tower I, New World International Trade Tower, 568 Jianshe Avenue, Jianghan District, Wuhan, Hubei 430022, P.R. China 电话/Tel : +86 27 8555 7988 传真/Fax : +86 27 8555 7588 www.zhonglun.com 北京中伦（武汉）律师事务所 关于武汉海特生物制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：武汉海特生物制药股份有限公司 北京中伦（武汉）律师事务所（以下简称"本所"）接受武汉海特生物制药 股份有限公司（以下简称"公司"）委托，指派本所律师对公司 2025 年第一次 临时股东大会（以下简称"本次股东大会"）的合法性进行见证并出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券 ...

证券代码：300683 证券简称：海特生物 公告编号：2025-048 武汉海特生物制药股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会召开期间没有增加、否决或变更议案情况发生； 3、本次股东大会采取现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开时间 （1）现场会议召开时间：2025 年 11 月 7 日（星期五）14:30。 （2）网络投票时间：2025 年 11 月 7 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 7 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过互联网 投票系统进行网络投票的具体时间为：2025 年 11 月 7 日 9:15 至 15:00 期间的 任意时间。 （二）现场会议召开地点 湖北省武汉市经济技术开发区海特科技园会议室。 （三）会议召集人：公司董事会 （四）会议召开方式：本次大会采取现场投票和网络投票相结合的方式。 2、本次股东大会 ...

Core Insights - HaiTe Bio announced on November 4 that as of October 31, 2025, the number of shareholders will reach 19,543 [2] Company Summary - HaiTe Bio is actively engaging with investors through interactive platforms, indicating a focus on shareholder communication and transparency [2] - The projected increase in shareholders to 19,543 suggests a growing interest in the company, which may reflect positively on its market position and investor confidence [2] Industry Context - The increase in shareholder numbers could indicate a broader trend in the biotechnology sector, where investor interest is crucial for funding and growth [2] - The company's engagement with investors may set a precedent for other firms in the industry, highlighting the importance of maintaining open lines of communication with stakeholders [2]

Core Viewpoint - Hite Bio's stock has shown significant volatility, with a year-to-date increase of 48.25%, but a notable decline of 40.98% over the past 60 days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Group 1: Stock Performance - As of November 3, Hite Bio's stock price reached 35.15 CNY per share, with a trading volume of 1.36 billion CNY and a market capitalization of 4.601 billion CNY [1]. - The stock has experienced a 7.20% increase over the last five trading days and a 3.08% increase over the last 20 days [1]. - The company has appeared on the "龙虎榜" (a stock market leaderboard) twice this year, with the most recent appearance on July 23 [1]. Group 2: Financial Performance - For the period from January to September 2025, Hite Bio reported a revenue of 422 million CNY, reflecting a year-on-year decrease of 6.45% [2]. - The net profit attributable to the parent company was -158 million CNY, marking a significant year-on-year decline of 297.78% [2]. Group 3: Business Overview - Hite Bio, established on April 8, 1992, and listed on August 8, 2017, is located in Wuhan Economic and Technological Development Zone and specializes in the research, production, and sales of innovative biopharmaceuticals [1]. - The company's revenue composition includes 57.20% from technical services, 25.59% from injectable mouse nerve growth factor, and 17.04% from injectable Epoetin [1]. Group 4: Shareholder Information - As of September 30, Hite Bio had 16,400 shareholders, an increase of 3.47% from the previous period, with an average of 7,426 circulating shares per shareholder, a decrease of 3.35% [2]. Group 5: Dividend Information - Since its A-share listing, Hite Bio has distributed a total of 85.2306 million CNY in dividends, with 17.0163 million CNY distributed over the past three years [3].